Coronary artery bypass grafting in patients with low ejection fraction

L Basiladze1, A Prangishvili, G Chapidze

  • 1Emergency Cardiology Center by Acad. G. Chapidze, Department of Cardiac Surgery, Tbilisi, Georgia.

Georgian Medical News
|December 10, 2009
PubMed

Insights

Coronary artery bypass grafting (CABG) is a viable option for patients with low ejection fraction (EF), despite increased risks. Selected patients with low EF undergoing CABG experienced good long-term survival and improved heart function.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Clinical Outcomes

Background:

  • Coronary artery disease (CAD) affects many patients, with low ejection fraction (EF) posing higher risks post-CABG.
  • Assessing the impact of low EF on clinical outcomes after CABG is crucial for patient selection and management.

Purpose of the Study:

  • To evaluate the effect of low ejection fraction (EF) on the clinical outcomes of patients undergoing coronary artery bypass grafting (CABG).

Main Methods:

  • A retrospective analysis of 1156 patients who underwent CABG between 2002-2009.
  • Patients were divided into two groups based on preoperative EF: Group I (EF ≤ 35%) and Group II (EF > 35%).
  • Outcomes including mortality, reoperation, respiratory failure, and long-term survival were analyzed.

Main Results:

  • Patients with low EF (Group I) had a higher incidence of postoperative respiratory failure.
  • Postoperative mortality was 4% in Group I, with no intraoperative or reoperation mortality.
  • Long-term survival was 95.8%, with significant EF improvement (>40%) in 82% of patients with low EF.

Conclusions:

  • Coronary artery bypass grafting (CABG) is a viable option for selected patients with low ejection fraction (EF), particularly those with angina and suitable coronary arteries.
  • Preoperative factors like previous myocardial infarction, heart failure, age, diabetes, and hypertension predict in-hospital complications.
  • Despite higher risks, CABG can lead to significant long-term survival and functional improvement in patients with compromised left ventricular function.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...